Luminespib protects against dexamethasone-induced hepatic, vascular, and metabolic abnormalities in rats
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025
DOI: 10.1007/s00210-025-04773-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Mohammed Fulayyih Aloufi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology & Toxicology, Faculty of Pharmacy, Mansoura University, El-Gomhoria Street, Mansoura, 35516, Egypt. Hauptthemen laut MEDLINE: Dexamethasone, Liver, Benzoquinones, Chemical and Drug Induced Liver Injury. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
Luminespib (LUM), a novel HSP90 inhibitor, has demonstrated promising effects in the oncology domain. However, no studies have explored the protective effects of LUM against dexamethasone (DEX)-induced metabolic and vascular toxicity, which provides an innovative approach to research. Adult male Wistar rats were intoxicated with DEX (8 mg/kg, i.p., q.d., for 6 days). In treatment groups, LUM was administered in two doses (2.5 and 5 mg/kg, i.p., q.o.d., for 6 days) 1 h before DEX administration. The results demonstrated that DEX-induced hepatic steatosis (NAFLD score), elevated liver enzymes (ALT, AST & LDH), aortic injury (aorta dissection score), and metabolic abnormalities (fasting insulin & OGTT) were significantly ameliorated by LUM treatment. According to our results, such outstanding improvements were attributed to (i) restoring cellular oxidant balance (GSH, MDA & NO), (ii) curbing NF-κB/TNF-α/MCP-1 inflammatory cascade, (iii) HSP90 inhibition with reduced expression of glucocorticoid receptors (GR), (iv) reduced expression of the endoplasmic reticulum stress sensors (CHOP & PERK), (v) activation of protein degradation pathways that degrade the misfolded GR including proteasomal degradation (20 S proteasome) and autophagy (BECLIN1). In conclusion, the findings in this study provide valuable insights into the therapeutic potential of LUM in protecting against DEX-induced deleterious effects on hepatic and aortic tissue in order to get the optimum therapeutic outcome from DEX.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology & Toxicology, Faculty of Pharmacy, Mansoura University, El-Gomhoria Street, Mansoura, 35516, Egypt.
- Department of Pharmacology & Toxicology, Faculty of Pharmacy, Mansoura University, El-Gomhoria Street, Mansoura, 35516, Egypt. sarahesham12@mans.edu.eg.
Zitieren
APA
Aloufi, M. F., Hazem, S. H., Abdelaziz, R. R., & Suddek, G. M. (2025). Luminespib protects against dexamethasone-induced hepatic, vascular, and metabolic abnormalities in rats. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04773-w
Vancouver
Aloufi MF, Hazem SH, Abdelaziz RR, Suddek GM. Luminespib protects against dexamethasone-induced hepatic, vascular, and metabolic abnormalities in rats. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-025-04773-w
BibTeX
@article{Aloufi2025,
author = {Aloufi, Mohammed Fulayyih and Hazem, Sara H and Abdelaziz, Rania R and Suddek, Ghada M},
title = {Luminespib protects against dexamethasone-induced hepatic, vascular, and metabolic abnormalities in rats},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
doi = {10.1007/s00210-025-04773-w}
}
EUVIMED